• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

玻璃浸出物作为生物制药制剂中游离脂肪酸颗粒形成的成核因子。

Glass Leachables as a Nucleation Factor for Free Fatty Acid Particle Formation in Biopharmaceutical Formulations.

机构信息

Pharmaceutical Development & Supplies, Pharma Technical Development Biologics Europe, F. Hoffmann-La Roche, Grenzacherstr. 124, CH-4070 Basel.

Pharmaceutical Development & Supplies, Pharma Technical Development Biologics Europe, F. Hoffmann-La Roche, Grenzacherstr. 124, CH-4070 Basel.

出版信息

J Pharm Sci. 2021 Feb;110(2):785-795. doi: 10.1016/j.xphs.2020.09.050. Epub 2020 Oct 7.

DOI:10.1016/j.xphs.2020.09.050
PMID:33035535
Abstract

Surfactants are essential components in protein formulations protecting them against interfacial stress. One of the current industry-wide challenges is enzymatic degradation of parenteral surfactants such as polysorbate 20 (PS20) and polysorbate 80, which leads to the accumulation of free fatty acids (FFAs) potentially forming visible particles over the drug product shelf-life. While the concentration of FFAs can be quantified, the time point of particle formation remains unpredictable. In this work, we studied the influence of glass leachables as nucleation factors for FFA particle formation. We demonstrate the feasibility of nucleation of FFA particles in the presence of inorganic salts like NaAlO and CaCl simulating relevant glass leachables. We further demonstrate FFA particle formation depending on relevant aluminum concentrations. FFA particle formation was subsequently confirmed with lauric/myristic acid in the presence of different quantities and compositions of glass leachables obtained by several sterilization cycles using different types of glass vials. We further verified the formation of particles in aged protein formulation containing degraded PS20 through the spiking of glass leachables. Particles were characterized as a complex of glass leachables, such as aluminum and FFAs. Based on our findings, we propose a likely pathway for FFA particle formation that considers specific nucleation factors.

摘要

表面活性剂是蛋白质制剂的重要组成部分,可保护其免受界面压力的影响。目前行业面临的挑战之一是聚山梨酯 20(PS20)和聚山梨酯 80 等注射用表面活性剂的酶降解,这会导致游离脂肪酸(FFA)的积累,从而在药物产品的保质期内形成可见颗粒。虽然可以定量测定 FFA 的浓度,但颗粒形成的时间点仍然难以预测。在这项工作中,我们研究了玻璃浸出物作为 FFA 颗粒成核因素的影响。我们证明了在存在无机盐如 NaAlO 和 CaCl 的情况下,FFA 颗粒成核的可行性,模拟了相关的玻璃浸出物。我们进一步证明了 FFA 颗粒的形成取决于相关的铝浓度。随后,通过使用不同类型的玻璃瓶进行多次灭菌循环获得的几种玻璃浸出物的不同数量和组成,在存在不同数量和组成的玻璃浸出物的情况下,确认了 FFA 颗粒的形成。我们还通过添加玻璃浸出物验证了含有降解 PS20 的老化蛋白质制剂中颗粒的形成。这些颗粒被表征为玻璃浸出物(如铝和 FFA)的复合物。基于我们的发现,我们提出了一种可能的 FFA 颗粒形成途径,该途径考虑了特定的成核因素。

相似文献

1
Glass Leachables as a Nucleation Factor for Free Fatty Acid Particle Formation in Biopharmaceutical Formulations.玻璃浸出物作为生物制药制剂中游离脂肪酸颗粒形成的成核因子。
J Pharm Sci. 2021 Feb;110(2):785-795. doi: 10.1016/j.xphs.2020.09.050. Epub 2020 Oct 7.
2
Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.提高生物制药制剂中游离脂肪酸粒子形成预测的准确性:在聚山梨酯 20 降解过程中考虑酯分布。
Mol Pharm. 2020 Nov 2;17(11):4354-4363. doi: 10.1021/acs.molpharmaceut.0c00794. Epub 2020 Oct 8.
3
Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation.评估一种改良的高纯度聚山梨酯 20,旨在降低游离脂肪酸颗粒形成的风险。
Pharm Res. 2021 Sep;38(9):1563-1583. doi: 10.1007/s11095-021-03087-9. Epub 2021 Sep 8.
4
Impact of Silicone Oil on Free Fatty Acid Particle Formation due to Polysorbate 20 Degradation.聚山梨酯 20 降解导致游离脂肪酸颗粒形成的硅酮油的影响。
Pharm Res. 2020 Oct 7;37(11):216. doi: 10.1007/s11095-020-02936-3.
5
Dissolution of Polysorbate 20 Degradation Related Free Fatty Acid Particles in Intravenous Bag Solutions.聚山梨酯 20 降解相关游离脂肪酸颗粒在静脉输液袋溶液中的溶解情况。
J Pharm Sci. 2021 Feb;110(2):687-692. doi: 10.1016/j.xphs.2020.10.004. Epub 2020 Oct 8.
6
Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations.理解颗粒形成:游离脂肪酸作为聚山梨酯20降解副产物在治疗性单克隆抗体制剂中的溶解度
Mol Pharm. 2015 Nov 2;12(11):3792-804. doi: 10.1021/acs.molpharmaceut.5b00310. Epub 2015 Oct 13.
7
A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.全油酸聚山梨酯 80 的综合评估:游离脂肪酸粒子形成、界面保护和氧化降解。
Pharm Res. 2021 Mar;38(3):531-548. doi: 10.1007/s11095-021-03021-z. Epub 2021 Mar 12.
8
Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.蛋白质制剂中的游离脂肪酸颗粒,第2部分:聚山梨酯原料的作用。
J Pharm Sci. 2015 Feb;104(2):447-56. doi: 10.1002/jps.24144. Epub 2014 Sep 5.
9
Stress-mediated polysorbate 20 degradation and its potential impact on therapeutic proteins.应激介导的聚山梨酯 20 降解及其对治疗性蛋白的潜在影响。
Pharm Res. 2024 Jun;41(6):1217-1232. doi: 10.1007/s11095-024-03700-7. Epub 2024 May 13.
10
Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism.生物制药制剂中聚山梨醇酯20的降解:游离脂肪酸的定量、颗粒的表征及降解机制的深入研究
Mol Pharm. 2015 Nov 2;12(11):3805-15. doi: 10.1021/acs.molpharmaceut.5b00311. Epub 2015 Oct 13.

引用本文的文献

1
Physicochemical Comparison of Kolliphor HS 15, ELP, and Conventional Surfactants for Antibody Stabilization in Biopharmaceutical Formulations.聚氧乙烯氢化蓖麻油HS 15、弹性蛋白样多肽(ELP)与传统表面活性剂在生物制药制剂中用于抗体稳定化的物理化学比较
Mol Pharm. 2025 Aug 4;22(8):4890-4908. doi: 10.1021/acs.molpharmaceut.5c00519. Epub 2025 Jun 27.
2
Polysorbates degrading enzymes in biotherapeutics - a current status and future perspectives.生物治疗药物中的聚山梨酯降解酶——现状与未来展望
Front Bioeng Biotechnol. 2025 Jan 10;12:1490276. doi: 10.3389/fbioe.2024.1490276. eCollection 2024.
3
Stability of Protein Pharmaceuticals: Recent Advances.
蛋白质类药物的稳定性:最新进展
Pharm Res. 2024 Jul;41(7):1301-1367. doi: 10.1007/s11095-024-03726-x. Epub 2024 Jun 27.
4
Comparative Stability Study of Polysorbate 20 and Polysorbate 80 Related to Oxidative Degradation.聚山梨醇酯20和聚山梨醇酯80与氧化降解相关的稳定性比较研究
Pharmaceutics. 2023 Sep 16;15(9):2332. doi: 10.3390/pharmaceutics15092332.
5
Oxidation of polysorbates - An underestimated degradation pathway?聚山梨酯的氧化——一种被低估的降解途径?
Int J Pharm X. 2023 Jul 27;6:100202. doi: 10.1016/j.ijpx.2023.100202. eCollection 2023 Dec 15.
6
Small-angle x-ray scattering investigation of the integration of free fatty acids in polysorbate 20 micelles.小角 X 射线散射研究游离脂肪酸在聚山梨酯 20 胶束中的整合。
Biophys J. 2023 Aug 8;122(15):3078-3088. doi: 10.1016/j.bpj.2023.06.011. Epub 2023 Jun 19.
7
Determination of Hyaluronic Acid Dermal Filler Impurities Using SEM/EDS Analysis.使用扫描电子显微镜/能谱分析(SEM/EDS)测定透明质酸真皮填充剂中的杂质
Polymers (Basel). 2023 Mar 26;15(7):1649. doi: 10.3390/polym15071649.
8
Instability Challenges and Stabilization Strategies of Pharmaceutical Proteins.药用蛋白质的稳定性挑战与稳定化策略
Pharmaceutics. 2022 Nov 20;14(11):2533. doi: 10.3390/pharmaceutics14112533.
9
Combining Machine Learning and Backgrounded Membrane Imaging: A Case Study in Comparing and Classifying Different Types of Biopharmaceutically Relevant Particles.结合机器学习和背景膜成像:在比较和分类不同类型的生物制药相关颗粒中的案例研究。
J Pharm Sci. 2022 Sep;111(9):2422-2434. doi: 10.1016/j.xphs.2022.05.022. Epub 2022 Jun 1.
10
Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation.评估一种改良的高纯度聚山梨酯 20,旨在降低游离脂肪酸颗粒形成的风险。
Pharm Res. 2021 Sep;38(9):1563-1583. doi: 10.1007/s11095-021-03087-9. Epub 2021 Sep 8.